Search

Your search keyword '"Bonotto M"' showing total 18 results
Start Over Author "Bonotto M" Publisher elsevier b.v.
18 results on '"Bonotto M"'

5. 416P Prognostic impact of liquid biopsy (LB) biomarkers at relapse on second-line (2L) treatment (Tx) after progression to endocrine therapy (ET) in metastatic breast cancer (mBC): Ancillary analysis of the MAGNETIC.1 study.

Author

Dri, A., Foffano, L., Molteni, E., Franzoni, A., Lay, L., Cucciniello, L., Da Ros, L., Buriolla, S., Bolzonello, S., Noto, C., Russo, S., Spazzapan, S., Nascimbeni, E., Pastò, B., Bonotto, M., Minisini, A.M.M., Damante, G., Belletti, B., Gerratana, L., and Puglisi, F.

Subjects
*METASTATIC breast cancer, *HORMONE therapy, *BIOMARKERS, *BIOPSY, *LIQUIDS
Published
2024
Full Text
View/download PDF

7. 261P Liquid biopsy–based biomarkers for the characterization of hormone receptor-positive (HR+) HER2-Low metastatic breast cancer (mBC).

Author

Bortot, L., Basile, D., Palmero, L., Dri, A., Cucciniello, L., Buriolla, S., Pastò, B., Mazzeo, R., Bonotto, M., Bolzonello, S., Franzoni, A., Allegri, L., Belletti, B., Damante, G., Gerratana, L., Minisini, A.M.M., and Puglisi, F.

Subjects
*METASTATIC breast cancer, *HORMONE receptor positive breast cancer, *BIOMARKERS, *LIQUIDS, *HORMONES
Published
2022
Full Text
View/download PDF

8. 249P A retrospective analysis on capecitabine and vinorelbine combination in metastatic breast cancer: The MARCELLINO study.

Author

de Scordilli, M., Bortot, L., Cucciniello, L., Totaro, F., Mazzeo, R., Alberti, M., Palmero, L., Targato, G., Dri, A., Pravisano, F., Zapelloni, G., Lisanti, C., Spazzapan, S., Minisini, A.M.M., Mansutti, M., Bonotto, M., Gerratana, L., Fasola, G., and Puglisi, F.

Subjects
*METASTATIC breast cancer, *VINORELBINE, *RETROSPECTIVE studies
Published
2022
Full Text
View/download PDF

10. 293P Exploring the interplay between tumor burden and liquid biopsy longitudinal evaluation in hormone receptor-positive, HER2-negative metastatic breast cancer (MBC).

Author

Mazzeo, R., Bortot, L., Michelotti, A., Buriolla, S., Palmero, L., Franzoni, A., Bertoli, E., Targato, G., Allegri, L., Da Ros, L., Alberti, M., Di Nardo, P., Bonotto, M., Sodde, S., Belletti, B., Spazzapan, S., Baldassarre, G., Damante, G., Gerratana, L., and Puglisi, F.

Subjects
*METASTATIC breast cancer, *HORMONE receptor positive breast cancer, *BIOPSY, *LIQUIDS, *TUMORS, *HORMONES
Published
2021
Full Text
View/download PDF

11. 261P Survival outcomes of triple-negative breast cancer (TNBC) patients in the pre-immunotherapy age: An analysis of Gruppo Italiano Mammella (GIM) 14 BIOMETA study with a focus on biological subtypes.

Author

Cerbone, L., Blondeaux, E., Boni, L., Ruelle, T., Russo, S., Bonotto, M., Targato, G., De Laurentiis, M., Piezzo, M., Arpino, G., Pugliese, P., Fabi, A., D'Alonzo, A., Giannubilo, I., Conte, B., Mulinelli, C., Lambertini, M., Bighin, C., and Del Mastro, L.

Subjects
*TRIPLE-negative breast cancer, *SURVIVAL rate
Published
2021
Full Text
View/download PDF

12. 294P Cell-free DNA (cfDNA) workflow for the risk definition of dose-limiting and recurrent neutropenia in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC).

Author

Palmero, L., Mazzeo, R., Buriolla, S., Bortot, L., Franzoni, A., Michelotti, A., Turra, G., Zilli, M., Stefani, E.C., Allegri, L., Di Nardo, P., Roncato, R., Bonotto, M., Cecchin, E., Belletti, B., Toffoli, G., Baldassarre, G., Damante, G., Gerratana, L., and Puglisi, F.

Subjects
*CYCLIN-dependent kinase inhibitors, *CELL-free DNA, *HORMONE therapy, *NEUTROPENIA, *WORKFLOW, *METASTATIC breast cancer
Published
2021
Full Text
View/download PDF

13. 295P Clinical characterization and outcome of a HER2-low metastatic breast cancer (mBC) cohort receiving first-line treatment (1L) with ET +/- CDK 4/6 inhibitor (CDKi).

Author

Bortot, L., Basile, D., Targato, G., Zara, D., Palmero, L., Alberti, M., Buriolla, S., Noto, C., Pascoletti, G., Poletto, E., Andreetta, C., Russo, S., Mansutti, M., Gerratana, L., Bonotto, M., Fasola, G., Puglisi, F., and Minisini, A.M.M.

Subjects
*CYCLIN-dependent kinases, *METASTATIC breast cancer, *TREATMENT effectiveness
Published
2021
Full Text
View/download PDF

15. 252 Poster - Lactate dehydrogenase as a prognostic biomarker in patients with hormone receptor-positive metastatic breast cancer treated with palbociclib: An exploratory cohort study.

Author

Pelizzari, G., Bertoli, E., Basile, D., Giavarra, M., Gerratana, L., Bartoletti, M., Lisanti, C., Corvaja, C., Vitale, M.G., Michelotti, A., Avoledo, D., Ros, L.Da, Bonotto, M., Bolzonello, S., Di Nardo, P., Fasola, G., Mansutti, M., Spazzapan, S., Minisini, A.M., and Puglisi, F.

Subjects
*BIOMARKERS, *CONFERENCES & conventions, *LACTATE dehydrogenase, *PROTEIN kinase inhibitors, *HORMONE receptor positive breast cancer
Published
2020
Full Text
View/download PDF

17. 236P - Clinical decision making and multidisciplinary team meetings (MDMs) in early breast cancer. Is the agreement between planned and applied therapeutic program?

Author

Giavarra, M., Bertoli, E., Buoro, V., Zara, D., Targato, G., Palmero, L., Vitale, M.G., Pelizzari, G., Basile, D., Gerratana, L., Bonotto, M., Andreetta, C., Cinausero, M., Pascoletti, G., Poletto, E., Russo, S., Puglisi, F., Fasola, G., Mansutti, M., and Minisini, A.M.

Subjects
*BREAST cancer, *DECISION making, *CANCER diagnosis, *HORMONE therapy, *DIAGNOSIS, *HORMONE receptor positive breast cancer
Abstract

Cancer multidisciplinary team meetings (MDMs) are commonly acknowledged as a good clinical practice. One of the roles of MDMs is to identify the best diagnostic and therapeutic strategies for patients (pts) with new diagnosis of early breast cancer (EBC). In this setting, the purpose of the study was to define whether there was agreement between the planned program (i.e. MDMs-based decision) and that actually applied (i.e. actual therapeutic choice, ATC). In addition, the study explored factors associated with discordance. We conducted a monocentric retrospective study of a consecutive series of 291 pts with new diagnosis of EBC, discussed at MDMs at the University Hospital of Udine (Italy), from January 2017 to June 2018. Median age was 62 years (range 27-88 years). Among invasive EBC patients, the most frequent phenotype was luminal-A (38%), followed by luminal-B (33%), HER2-positive (12%) and triple negative (5%). Thirty-four pts (12%) had diagnosis of in situ carcinoma (DCIS). Median time from MDMs discussion to first oncological examination was two weeks. Rate of discordance between MDMs-based decision and final choice, during face to face consultation with the oncologist, was 15.8% (46/291). Among cases with discordance, 19 pts (41.3%) had age > 70 years; 8 pts (17%) had a diagnosis of DCIS, 13 pts (28%) luminal-B carcinoma, 12 pts (26%) luminal-A, 9 pts (20%) HER2-positive and 4 pts (9%) triple negative EBC. The most frequent reason for changing the MDMs-based program was clinical decision by the oncologist at the first evaluation (87%). Follow-up was preferred to the chemotherapy proposed within the MDMs by 15% of pts, and to the endocrine therapy in 39% cases (among these, 44.5% had diagnosis of DCIS). In our study 16/46 pts (35%) had a therapeutic change from chemotherapy to endocrine therapy: among these pts, 7/16 had a luminal-B and 6/16 had a HER2-positive disease. Further analysis aiming at evaluating variables which could predict discordance between MDMs proposal and face to face oncological consultation are ongoing. The results of our study could be useful for enhance the role of MTD and identify unmet needs in decision making process in EBC. The authors. Has not received any funding. All authors have declared no conflicts of interest. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results